U.S., Sept. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07168226) titled 'Phase 2 Cachexia Clinical Trial to Evaluate the Efficacy and Safety of ASCA101' on Aug. 26.
Brief Summary: The goal of this clinical trial is to evaluate the efficacy and safety of ASCA101 for the treatment of Cachexia in solid tumor patients. The main questions it aims to answer are:
Can the efficacy of ASCA101 in improving cachexia be evaluated based on changes in body weight measured by InBody after 12 weeks (3 cycles) of weekly administration, compared to baseline, for each dose group?
Do participants experience adverse events during administration of ASCA101 and/or within 4 weeks after the end of administration?
This clinic...